Skip to main content

1243 results

Publication

Buyback programs - October 2025

Monthly communication regarding buyback programs
Publication

Sales at end september 2025

9-month sales: €384 million (-1.3% at constant exchange rates and -3.5% on a reported basis) 9-month sales of Essential products: €244 million (64% of sales, +2.7% at constant exchange rates and +1.1% on a reported basis)
Publication

Monthly information regarding the total number of voting rights – September 2025

As per articles L233‐8‐II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »
Publication

Buyback programs - September 2025

Monthly communication regarding buyback programs
Basic page

FAQ Phovia®

Is it okay to use post-surgical on orthopaedics who have had surgical implants? Yes it can be used on post-surgical patient with implants including plates, screws and pins. Red light laser is not used for approx. 24 hours after surgery as it can increase blood flow therefore excessive bleeding. Is...
News

2025 half-year Results

Sales: €258m (-1.0% at constant exchange rates) Essential products sales: €165m (+4.2% at constant )exchange rates Net income, Group share: €25m (9.7% of sales) EBITDA: €53m (20.4% of sales) Cash flow generation: €51m The Board of Directors of Vetoquinol SA, meeting on September 9, 2025, approved...
Publication

2025 Half-Year Results

Sales: €258m (-1.0% at constant exchange rates) Essential products sales: €165m (+4.2% at constant exchange rates) Net income, Group share: €25m (9.7% of sales) EBITDA: €53m (20.4% of sales) Cash flow generation: €51m
Publication

Rapport financier semestriel 2025 (french)

Rapport financier semestriel 2025 (french)
Publication

2025 Half-Year Results

Contents: 01. Activity for the first half of 2025 02. Consolidated results for the first half of 2025 03. Strategy and outlook
Publication

Monthly information regarding the total number of voting rights – August 2025

As per articles L233‐8‐II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »